Previously recorded as Advanced Medical Optics, Inc. (to 2009)
31 patents currently held
267 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2027. from the record
Of the 267 now held by other companies, 258 name Johnson and Johnson Surgical Vision Inc. as their current owner, and 9 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Oct 2027
Next term end
28
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2028 · High confidence
Also notable
Ends Dec 2033 · High confidence
Also notable
Ends Nov 2029 · High confidence
Also notable
Ends May 2030 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends Mar 2034 · High confidence
Systems and Methods for Transverse Phacoemulsification
US 10,478,336
Cited by 52 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2028.
Computer-Based Operating Room Support System
US 11,715,560
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2033.
Automatically Switching Different Aspiration Levels And/Or Pumps to an Ocular Probe
US 10,238,778
Cited by 19 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2029.
Intraocular lens for correcting corneal coma
US 8,801,781
The most cited patent in this portfolio, cited by 61 later US patents, top 10% of utility patents granted in 2014 in our data. Protection runs to 2030.
Fluidics Cassette for Ocular Surgical System
US 11,065,153
Granted 2021. Computed term ends 2027.
Valve System of Surgical Cassette Manifold, System, and Methods Thereof
US 10,857,029
A family of 13 related applications built on the 2020 grant. Protection runs to 2034.
Formerly held, still cited
Notable
Ends Jun 2034 · High confidence
Cited by 48 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
now held by Johnson & Johnson Surgical Vision, Inc.
Also notable
Ends Nov 2029 · High confidence
Cited by 86 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2029.
now held by Johnson & Johnson Surgical Vision, Inc.
Also notable
Ends Aug 2028 · High confidence
Cited by 99 later US patents, top 10% of utility patents granted in 2009 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Johnson & Johnson Surgical Vision, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Phacoemulsification Surgical Multi-Use Pack Usage Tracker System (US 10,363,111) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Computer-Based Operating Room Support System (US 11,715,560) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Systems and Methods for Transverse Phacoemulsification (US 10,478,336) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Advanced Occlusion Management Methods for a Phacoemulsification System (US 11,969,380) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 2 fees due Nov 12, 2027
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 11 terms have ended since Aug 23, 2026
- Nov 9 US 9,757,275 Critical Alignment of Fluidics Cassettes · term ended
- Nov 9 US 11,058,577 Fluidics Cassette for Ocular Surgical System · term ended
- Nov 9 US 10,441,461 Critical Alignment of Fluidics Cassettes · term ended
- Nov 1 US 8,034,067 Vacuum Sense Control for Phaco Pulse Shaping · term ended
- Oct 23 US 10,105,215 Intraocular Lens and Methods for Providing Accommodative Vision · lapsed on the fee record
- Oct 23 US 10,105,214 Accommodating Intraocular Lens Providing Progressive Power Change · lapsed on the fee record
- Oct 17 US 7,662,180 Accommodating Intraocular Lens and Method of Manufacture Thereof · term ended
- Oct 4 US 8,715,220 Systems and Methods for Power and Flow Rate Control · term ended
- Sep 27 US 9,149,568 Systems and Methods for Power and Flow Rate Control · term ended
- Sep 9 US 8,828,412 Stable Polyphenol Containing Ophthalmic Emulsion for Treating Dry Eyes · lapsed on the fee record
- Aug 26 US 8,814,934 Multifocal Accommodating Intraocular Lens · lapsed on the fee record
What they patent
The largest of its 28 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,065,153 | Fluidics Cassette for Ocular Surgical System In force · High confidence | In force | High confidence | |
| US 10,478,336 | Systems and Methods for Transverse Phacoemulsification In force · High confidence | In force | High confidence | |
| US 8,439,498 | Toric Intraocular Lens with Modified Power Characteristics In force · High confidence | In force | High confidence | |
| US 10,238,778 | Automatically Switching Different Aspiration Levels And/Or Pumps to an Ocular Probe In force · High confidence | In force | High confidence | |
| US 10,251,983 | Automatically Switching Different Aspiration Levels And/Or Pumps to an Ocular Probe In force · High confidence | In force | High confidence | |
| US 11,369,728 | Automatically Switching Different Aspiration Levels And/Or Pumps to an Ocular Probe In force · High confidence | In force | High confidence | |
| US 11,369,729 | Automatically Switching Different Aspiration Levels And/Or Pumps to an Ocular Probe In force · High confidence | In force | High confidence | |
| US 8,801,781 | Intraocular lens for correcting corneal coma In force · High confidence | In force | High confidence | |
| US 9,480,645 | OMEGA-3 Oil Containing Ophthalmic Emulsions In force · Medium confidence | In force | Medium confidence | |
| US 9,817,246 | Multifocal Lens Having an Optical Add Power Progression, and a System and Method of Providing Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 31: 267 patents in force now held by others · 238 patents ended · 5 applications pending · 75 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.